Last reviewed · How we verify
depakine chrono
Depakine Chrono (valproic acid) increases brain GABA levels and inhibits histone deacetylase, enhancing inhibitory neurotransmission and gene expression.
Depakine Chrono (valproic acid) increases brain GABA levels and inhibits histone deacetylase, enhancing inhibitory neurotransmission and gene expression. Used for Epilepsy and seizure disorders, Bipolar disorder (acute mania), Migraine prophylaxis.
At a glance
| Generic name | depakine chrono |
|---|---|
| Sponsor | Sanofi |
| Drug class | Anticonvulsant / Mood stabilizer |
| Target | GABA metabolism; histone deacetylase |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Valproic acid is a branched-chain fatty acid that enhances GABAergic neurotransmission by inhibiting GABA catabolism and increasing GABA synthesis. It also acts as a histone deacetylase inhibitor, modulating gene expression. These combined effects reduce neuronal excitability and stabilize mood, making it effective for seizure control and mood stabilization.
Approved indications
- Epilepsy and seizure disorders
- Bipolar disorder (acute mania)
- Migraine prophylaxis
Common side effects
- Tremor
- Weight gain
- Alopecia (hair loss)
- Thrombocytopenia
- Hepatotoxicity
- Pancreatitis
- Nausea
- Sedation
Key clinical trials
- Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets (PHASE1)
- Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects. (PHASE1)
- Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome (PHASE2)
- Bioequivalence Study of Sodium Valproate and Valproic Acid Tablets (PHASE4)
- Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes (PHASE2)
- Valproic Acid for Idiopathic Nephrotic Syndrome (PHASE2, PHASE3)
- Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- depakine chrono CI brief — competitive landscape report
- depakine chrono updates RSS · CI watch RSS
- Sanofi portfolio CI